Radiopharmaceutical therapy of chronic inflammatory knee joint disease

Comparison of radiosynovectomy efficacy with Re 188 sulfur colloid and Y-90 colloid in patient with chronic inflammatory knee joint disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201112251100N4

Enrollment

Registered

2012-01-03

Start date

2012-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis of knee joint. Seropositive rheumatoid arthritis

Interventions

Intervention 1: Second group: Intra-articular injection of a single dose (10 mCi) of Re-188 sulfur colloid. Intervention 2: Third group (Control): Intra-articular injection of a single dose (40 mg) of

Treatment - Drugs

Second group: Intra-articular injection of a single dose (10 mCi) of Re-188 sulfur colloid.

Third group (Control): Intra-articular injection of a single dose (40 mg) of Triamcinolon.

First group: Intra-articular injection of a single dose (5 mCi) of Y-90 hydroxyapatite colloid.

Eligibility

Sex/Gender

All

Age

20 Years to 149 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients (>20 yr) with chronic arthritis of knee joint who have the following characteristics including chronic knee pain with no treatment response to NSAIDS and DMARDs for three months, positive blood pool phase in bone scan, absence of Baker cyst in ultrasond, absence of pregnancy and breastfeeding, no intra-articular injection of corticosteroids in the past 6 weeks, absence of knee surgery in the past 8 weeks, no removal of synovial fluid in the past 2 weeks, no severe damage or traumato the knee joint, absence of skin infection at the injection site. Exclusion criteria: improper injection of radiopharmaceutical and Lack of patient cooperation during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Clinical assessment of the patients. Timepoint: 1, 3 and 6 months after radiopharmaceutical injection. Method of measurement: Standardized questionaire.	—

Secondary

Measure	Time frame
Analgesic consumption. Timepoint: 1, 3 and 6 months after radiopharmaceutical injection. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Babak Fallahi

Research Institute for Nuclear Medicine, Tehran University of Medical Sciences

bfallahi@sina.tums.ac.ir+98 21 8822 0361

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026